(via NewsDirect)
Emyria Ltd (ASX:EMD) MD Michael Winlo tells Proactive the company has expanded its proprietary cannabinoid medicine pipeline, with the launch of a high potency, highly bioavailable Ultra-Pure CBD dose form called EMD-RX9, targeting prescription-based registrations. The launch follows the company’s recent commercialisation success of its low-dose CBD capsule, EMD-RX5 with Aspen Pharmacare (JSE:APN) in Australia.
Contact Details
Proactive Investors
Jonathan Jackson
+61 413 713 744
Copyright (c) 2023 TheNewswire - All rights reserved.
Copyright (c) 2023 TheNewswire - All rights reserved., source Press Releases